DelveInsight’s “Chronic Pruritus – Market Insight, Epidemiology, And Market Forecast – 2034″ report offers an in-depth understanding of the Chronic Pruritus, historical and forecasted epidemiology as well as the Chronic Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Some of the key facts of the Chronic Pruritus Market Report:
• According to DelveInsight, the market for Chronic Pruritus in the 7MM is expected to witness notable growth during the study period from 2020 to 2034.
• The 12-month cumulative incidence of chronic pruritus in the general population may be as high as ~7%.
• KORSUVA (difelikefalin) is the first FDA-approved treatment for Chronic Kidney Disease-Associated Pruritus (CKD-aP).
• Other treatments for chronic pruritus include topical and systemic corticosteroids, antihistamines, immunomodulators, phototherapy, and other off-label medications.
• In Dec 2024, Galderma received U.S. FDA approval for Nemluvio® (Nemolizumab) for patients with moderate-to-severe atopic dermatitis.
• In Aug 2024, Galderma received U.S. FDA approval for Nemluvio® (Nemolizumab) for adult patients living with prurigo nodularis.
• In May 2024, Clexio reached the 50% enrollment milestone in the CLE-400 Phase II proof-of-concept study for subjects suffering from chronic pruritus associated with Notalgia Paresthetica.
• Emerging drugs in the chronic pruritus pipeline include Dupixent, CLE-400, and others.
• Key players in the chronic pruritus market include Sanofi, Keymed Biosciences, Bellus Health, Clexio Biosciences, and others.
To Know in detail about the Chronic Pruritus market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Chronic Pruritus Market Forecast
Chronic Pruritus Overview
Chronic pruritus (persistent itching) is a distressing condition lasting for more than six weeks, often associated with dermatological, neurological, systemic, or psychogenic disorders. Common causes include eczema, psoriasis, chronic kidney disease, diabetes, and nerve disorders. The persistent itch significantly impacts quality of life, leading to sleep disturbances, anxiety, and depression. Management depends on the underlying cause and may involve antihistamines, corticosteroids, immunomodulators, or targeted biologics.
Get a Free sample for the Chronic Pruritus Market Report: https://www.delveinsight.com/report-store/chronic-pruritus-market
Chronic Pruritus Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Pruritus Epidemiology Segmentation:
The Chronic Pruritus epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Prevalence-specific cases of chronic pruritus
• Disease-specific cases of chronic pruritus
Download the report to understand which factors are driving Chronic Pruritus epidemiology trends @ Chronic Pruritus Epidemiology Forecast
Chronic Pruritus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Pruritus market or expected to be launched during the study period. The analysis covers the market uptake of chronic pruritus by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Pruritus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chronic Pruritus Market Strengths
• New insights into the neurological pathways of chronic itch are driving novel treatment developments.
• The growing recognition of chronic pruritus as a serious condition fuels demand for effective therapies.
Chronic Pruritus Market Weaknesses
• Many current treatments provide only symptomatic relief without addressing the root cause.
• Patients with refractory pruritus often struggle to find effective and long-term solutions.
Scope of the Chronic Pruritus Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Pruritus Therapies: Dupixent, CLE-400, and others.
• Key Chronic Pruritus Companies: Sanofi, Keymed Biosciences, Bellus Health, Clexio Biosciences, and others.
• Chronic Pruritus Therapeutic Assessment: Chronic Pruritus currently marketed and Chronic Pruritus emerging therapies
• Chronic Pruritus Market Dynamics: Chronic Pruritus market drivers and Chronic Pruritus market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Chronic Pruritus Unmet Needs, KOL’s views, Analyst’s views, Chronic Pruritus Market Access and Reimbursement
To learn more about the key players and advancements in the Chronic Pruritus Treatment Landscape, visit the Chronic Pruritus Market Analysis Report
Table of Contents
1. Chronic Pruritus Market Report Introduction
2. Executive Summary for Chronic Pruritus
3. SWOT analysis of Chronic Pruritus
4. Chronic Pruritus Patient Share (%) Overview at a Glance
5. Chronic Pruritus Market Overview at a Glance
6. Chronic Pruritus Disease Background and Overview
7. Chronic Pruritus Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Pruritus
9. Chronic Pruritus Current Treatment and Medical Practices
10. Chronic Pruritus Unmet Needs
11. Chronic Pruritus Emerging Therapies
12. Chronic Pruritus Market Outlook
13. Country-Wise Chronic Pruritus Market Analysis (2020–2034)
14. Chronic Pruritus Market Access and Reimbursement of Therapies
15. Chronic Pruritus Market Drivers
16. Chronic Pruritus Market Barriers
17. Chronic Pruritus Appendix
18. Chronic Pruritus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/